Basecamp Research Raises $140M Series C Led by S32

Basecamp Research has raised a $140 million Series C round to train the next generation of its EDEN biological foundation models and advance its AI-designed therapeutics pipeline toward clinical development. The company, headquartered in London with offices and labs in Cambridge, Massachusetts, announced the oversubscribed financing on September 23, 2026.

S32 led the round, with participation from Anthropic's Anthology Fund and NVIDIA. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp Research's Board of Directors.

"We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research. He said the funding moves the technology closer to patients who currently have few alternatives.

Who else invested?

The syndicate also included Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.

Senior leaders across pharma, biotech and global industry also invested, including André Hoffmann, Vice-Chairman of Roche. Hoffmann described personalised, AI-designed therapeutics as the next transformation of a biotechnology revolution that began fifty years ago, and said Basecamp Research has built the platform to deliver it.

Conrad said combining AI, biological data and scientific insight could transform how disease is understood and medicines are discovered. He described the company as building an important technology platform at the center of that opportunity.

What does the money fund?

The financing will cover three main lines of work:

• Training a new generation of the EDEN models
• Advancing the AI-designed therapeutics pipeline toward clinical development
• Expanding pharmaceutical partnerships, supported by the appointment of Richard Pearce, formerly of Biogen, as Chief Business Officer

Basecamp is applying EDEN to in vivo cell therapy, an approach that reprograms a patient's cells inside the body. The company characterizes current cell therapies as constrained in the complexity of what they can deliver and dependent on manufacturing that costs hundreds of thousands of dollars per patient.

Its platform combines EDEN's design of long, complex DNA sequences with large serine recombinases intended to integrate those sequences into the genome. The goal, the company says, is cell therapies that are more sophisticated and customisable yet simpler to administer, with potential application against cancer and autoimmune disease. Basecamp said it has demonstrated strong preclinical results across multiple modalities and disease areas.

How big is the data behind EDEN?

The platform's core asset is the Trillion Gene Atlas, which the company describes as the world's largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.

On its website, Basecamp describes EDEN as a 28B-parameter model. The company states its dataset holds over 100 billion novel genes at over 100T tokens, with therapeutic platforms spanning gene insertion, gene editing and peptide design advancing through preclinical development.

The company says the EDEN models recognize patterns across a broad range of previously unseen biology and are built to understand how DNA works across all of life rather than to perform a single scientific task. According to Basecamp, the models can produce potential therapeutic candidates directly from disease information, an approach demonstrated through its collaboration with Anthropic on Claude Science. Their capabilities include designing cell and gene therapies, enzymes and peptides.

What has Basecamp already proven?

The Series C caps a year of milestones. On March 18, 2026, Basecamp launched the Trillion Gene Atlas at SXSW in Austin and NVIDIA's GTC conference in San Jose, setting a goal of expanding known evolutionary genetic diversity 100-fold by collecting genomic data from more than 100 million species across thousands of sites.

The EDEN foundation models were first released in January 2026 and trained entirely on BaseData, a proprietary genomic database the company describes as more than ten times larger than all public resources combined, spanning 10 billion genes new to science across 1 million newly discovered species.

In wet-lab validation, Basecamp reported:

• Zero-shot activity for EDEN in primary human T-cells
• Hits across multiple frontier modalities, including what it calls AI-Programmable Gene Insertion, a technique for inserting healthy genes
• A 97% hit rate for designed antimicrobial peptides against priority pathogens

On June 30, 2026, the company brought EDEN's antibiotic design and vaccine target prediction models to Claude, including Claude Science, Anthropic's AI workbench for life sciences research. The capability is available through Anthropic's connectors directory in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork and Claude Science.

In a collaboration with University of Pennsylvania researchers led by César de la Fuente, 97% of EDEN-designed antibiotic peptides proved active against World Health Organisation priority pathogens in laboratory testing. A candidate designated EDEN-7 showed efficacy in the same range as a last-line antibiotic in mice infected with multidrug-resistant Acinetobacter baumannii, despite being generated without subsequent optimization or iterative engineering, the company said.

With $140 million in hand and a new investor bench that includes S32, Anthropic and NVIDIA, Basecamp Research now faces the step that separates AI-drug discovery companies from their peers: moving EDEN-designed therapeutics from strong preclinical data into clinical development.